IRIS UniCatt

Giampietro, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.123
AS - Asia 3.634
EU - Europa 3.480
SA - Sud America 871
Continente sconosciuto - Info sul continente non disponibili 179
AF - Africa 108
OC - Oceania 9
AN - Antartide 1
Totale 14.405
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.918
SG - Singapore 1.548
DE - Germania 1.142
CN - Cina 790
BR - Brasile 694
IT - Italia 627
VN - Vietnam 462
SE - Svezia 424
FR - Francia 278
UA - Ucraina 186
GB - Regno Unito 168
BD - Bangladesh 167
IE - Irlanda 123
IN - India 119
RU - Federazione Russa 115
FI - Finlandia 111
ID - Indonesia 109
CA - Canada 101
JP - Giappone 101
PL - Polonia 89
HK - Hong Kong 82
AR - Argentina 68
NL - Olanda 55
MX - Messico 53
IQ - Iraq 39
ES - Italia 35
TR - Turchia 33
EC - Ecuador 29
ZA - Sudafrica 28
AT - Austria 27
CO - Colombia 26
BE - Belgio 25
KR - Corea 20
PK - Pakistan 19
VE - Venezuela 19
SA - Arabia Saudita 18
EG - Egitto 17
AE - Emirati Arabi Uniti 15
IR - Iran 15
MA - Marocco 14
UZ - Uzbekistan 13
CL - Cile 12
JM - Giamaica 11
MY - Malesia 11
PE - Perù 11
PH - Filippine 10
AZ - Azerbaigian 9
CI - Costa d'Avorio 9
KE - Kenya 9
PT - Portogallo 9
AL - Albania 8
CR - Costa Rica 8
CZ - Repubblica Ceca 8
KZ - Kazakistan 8
PY - Paraguay 8
MD - Moldavia 7
RO - Romania 7
TN - Tunisia 7
JO - Giordania 6
LK - Sri Lanka 6
BG - Bulgaria 5
BS - Bahamas 5
DO - Repubblica Dominicana 5
GR - Grecia 5
GT - Guatemala 5
HN - Honduras 5
NP - Nepal 5
AU - Australia 4
CH - Svizzera 4
LB - Libano 4
OM - Oman 4
RS - Serbia 4
SN - Senegal 4
AM - Armenia 3
BH - Bahrain 3
ET - Etiopia 3
EU - Europa 3
GE - Georgia 3
HU - Ungheria 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BB - Barbados 2
BO - Bolivia 2
BY - Bielorussia 2
DK - Danimarca 2
GA - Gabon 2
GH - Ghana 2
IL - Israele 2
KG - Kirghizistan 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
QA - Qatar 2
SC - Seychelles 2
SV - El Salvador 2
TH - Thailandia 2
UY - Uruguay 2
AD - Andorra 1
AO - Angola 1
AQ - Antartide 1
Totale 14.203
Salva come PNG Salva come JPEG
Città #
Singapore 853
Ashburn 620
Chandler 582
San Jose 582
New York 235
Ho Chi Minh City 167
Beijing 163
Los Angeles 163
Rome 149
Dublin 115
San Mateo 110
Hanoi 101
Lauterbourg 92
Milan 89
Dallas 88
Jakarta 87
The Dalles 86
Ann Arbor 82
Tokyo 82
Hefei 80
Warsaw 77
Jacksonville 76
Moscow 76
Hong Kong 73
Munich 73
São Paulo 73
Wilmington 72
Fairfield 68
Frankfurt am Main 65
Marseille 63
Boston 61
Santa Clara 61
Tukwila 58
Nürnberg 55
St Louis 54
Chicago 52
Houston 51
Nanjing 48
Helsinki 45
Seattle 45
Bremen 44
Buffalo 44
Princeton 41
Cattolica 40
Montreal 38
Atlanta 36
Dearborn 34
Orem 33
Denver 32
Boardman 31
Redwood City 31
Brooklyn 30
Kent 30
Shanghai 30
London 29
Woodbridge 29
Turku 26
Cambridge 25
Phoenix 25
Brussels 24
Da Nang 24
Nanchang 24
Nuremberg 23
Rio de Janeiro 23
Hangzhou 22
Lawrence 22
Mountain View 20
Zhengzhou 19
North Bergen 18
Guangzhou 17
Hyderabad 17
Las Vegas 17
University Park 17
Amsterdam 16
Belo Horizonte 16
Augusta 15
Mexico City 15
Mumbai 15
Seoul 15
Shenyang 15
Toronto 15
Council Bluffs 14
Fremont 14
Haiphong 14
Johannesburg 14
San Francisco 14
Paris 13
Poplar 13
Vienna 13
Baghdad 12
Düsseldorf 12
Norwalk 12
Stockholm 12
Tashkent 12
Bexley 11
Dhaka 11
Elk Grove Village 11
Guayaquil 11
Kunming 11
Lappeenranta 11
Totale 7.044
Salva come PNG Salva come JPEG
Nome #
Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism. 503
Hypophysitis Outcome and Factors Predicting Responsiveness to Glucocorticoid Therapy: A Prospective and Double-Arm Study. 365
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries 334
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 312
Isolated growth hormone deficiency: clinical entity? 292
Double pituitary adenomas 244
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors 232
Role of a mini-invasive approach in the diagnosis and treatment of tubo-peritoneal infertility as an altenative to IVF [Il ruolo di un approccio chirurgico mini-invasivo nella diagnosi e trattamento della sterilità tubo-peritoneale in alternativa alla FIVET] 230
Coenzyme Q10 evaluation in pituitary-adrenal axis disease: preliminary data. 219
Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels 218
Typical and Atypical Pituitary Adenomas: A Single-Center Analysis of Outcome and Prognosis 214
An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Single Prospective Monocentric Experience 211
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 206
Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study 206
Effects of gherlin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome 205
Male fertility and reduction in semen parameters: A single tertiary-care center experience 198
Circulating endothelial cells as marker of endothelial damage in male hypogonadism 194
NOVEL BIOMARKERS OF ANDROGEN DEFICIENCY FROM SEMINAL PLASMA PROFILING USING HIGH-RESOLUTION MASS SPECTROMETRY. 185
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study 182
Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study 173
The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency: report of four cases and review of the literature 166
Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome 164
Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study 163
Influence of diabetes mellitus on vertebral fractures in men with acromegaly 162
Circulating endothelial cells as marker of endothelial damage in male hypogonadism 162
The Changing Clinical Spectrum of Hypophysitis 157
Significant GH-deficiency after long-term cure by surgery in adult patients with Cushing s disease 156
DIAGNOSIS OF ENDOCRINE DISEASE: Primary Empty Sella: a comprehensive review 156
Radically resected pituitary adenomas: prognostic role of Ki67 labeling index in monocentric retrospective series and literature review 154
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 154
Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency 152
Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues 149
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. 148
Fertility and hypopituitarism 147
GH receptor isoforms and skeletal fragility in acromegaly 144
Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results 144
Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways 140
Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second Line Therapies: A Longitudinal Study 139
CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs 134
Hypothalamitis and pituitary atrophy 134
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes 133
Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors. 133
Quantitative Analysis of the Seminal Plasma Proteome in Secondary Hypogonadism 132
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy 131
Genes of the “regulation of lymphocyte activation” pathway may influence immune cells infiltration in growth hormone secreting pituitary tumors 130
First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. 129
Trouillas's Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 128
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 126
The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype? 125
Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients 124
Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy 123
Empty sella syndrome: Multiple endocrine disorders. 123
Synchronous Bilateral Adrenalectomy in ACTH-dependent Hypercortisolism: Predictors, Biomarkers and Outcomes 122
Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review 120
Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis 118
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 117
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin? 116
Acromegaly in the elderly patients 116
Pregnancy in Autoimmune Hypophysitis: Management of a Rare Condition 115
The Role of Growth Hormone Receptor Isoforms and Their Effects in Bone Metabolism and Skeletal Fragility 114
Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry 113
Understanding the effect of acromegaly on the human skeleton. 113
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 112
Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients. 111
Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. 111
Vertebral fractures in patients with acromegaly: a 3-year prospective study 109
The Differential Diagnosis between Pseudo Cushing's Syndrome and True Cushing's Syndrome in a Septic Patient in the Pre-Agonal Phase: A Case Report 108
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. 108
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant 108
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly 104
The multi-biomarker acro-TIME score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort 103
Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study 103
Empty sella syndrome: an update 102
Cytokines and chemokines modulate the growth of pituitary adenoma/neuroendocrine tumors: preliminary results of a monocenter prospective pilot study 100
Clinical management of teratoma, a rare hypothalamic-pituitary neoplasia 100
Trouillas’s Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 99
Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients 97
Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. 94
Acromegaly can be cured by first-line pasireotide treatment? 93
Second line treatment of acromegaly: Pasireotide or Pegvisomant? 92
De-escalation treatment with pasireotide for acromegaly: a long-term experience 90
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience 88
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 88
Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients? 87
Solitary Metastatic Melanoma of the Pituitary Gland: Report of Two Cases and Literature Review 86
GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study 84
Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis 84
Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life 84
A Toluene-induced Infundibulo-neuro-hypophysitis: Presentation of a New Cause of Hypophysitis Secondary to Toxic Exposure and Review on Toluene Inhalation Endocrine Effects 82
The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohort 80
Colon Cancer Presenting as Pituitary Mass and Hypopituitarism: Recognition and Multidisciplinary Approach of a Rare Case 80
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study 77
Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences 75
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 74
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly 71
Lights or shadows, a promising future for positron emission tomography in pituitary tumors: a systematic review 67
Vitamin D in pituitary driven osteopathies 67
Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: a pilot study 66
Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly 66
Bone safety of dual-release hydrocortisone in patients with hypopituitarism. 65
Totale 14.064
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.606
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.606
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022554 0 0 7 47 74 27 10 112 28 26 85 138
2022/20231.516 173 207 123 252 80 211 89 127 157 13 53 31
2023/2024717 32 160 17 32 31 142 35 8 28 34 93 105
2024/20251.843 30 40 124 75 101 74 37 67 273 188 395 439
2025/20266.041 736 221 421 769 846 287 884 313 297 432 590 245
2026/20271.428 411 717 300 0 0 0 0 0 0 0 0 0
Totale 14.405